FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154936148> ?p ?o ?g. }

• W2154936148 endingPage "666" @default.
• W2154936148 startingPage "661" @default.
• W2154936148 abstract "Background:Concurrent chemoradiotherapy is the current standard treatment for inoperable stage III non-small cell lung cancer (NSCLC). In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) in patients with inoperable stage III NSCLC followed in our oncology clinic. Material andMethods:Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. Cisplatin (30 mg/m2) and vinorelbine (20 mg/m2) were administered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation chemotherapy were given. All patient data, including pathological, clinical, radiological, biochemical, and hematological data, were assessed retrospectively using our database system. Results:Our study included 97 unresectable stage III NSCLC patients who were treated with CCRT. Median age was 58 years old (range 39–75) and 87 (89.7%) of the patients were men. ECOG performance score was 0–1 in 93 patients (95.9%). Squamous histology, the most common histology, was diagnosed in 46 patients (47.4%). Median follow-up time was 23.8 months. Median progression-free survival (PFS) and median overall survival time (OS) were 10.3 months and 17.8 months, respectively. Objective response rate and clinical benefit rate were 75.3% and 83.5%, respectively. Distant and local relapse rate were 57.1% and 42.9%, respectively. Hematological and non-hematological grade 3–4 toxicities were seen in 13 (13.4%) and 16 (16.5%) patients, respectively. Six (6.1%) patients died due to toxicity. Conclusions:The results of this study suggest that split-dose cisplatin may offer fewer grade III–IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. Similar to past studies, despite high response rate during CCRT, distant relapse is the major parameter that influences patient survival in long-term in NSCLC." @default.
• W2154936148 created "2016-06-24" @default.
• W2154936148 creator A5030366726 @default.
• W2154936148 date "2015-01-01" @default.
• W2154936148 modified "2023-10-12" @default.
• W2154936148 title "Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience" @default.
• W2154936148 cites W1926988225 @default.
• W2154936148 cites W1944220675 @default.
• W2154936148 cites W1985213644 @default.
• W2154936148 cites W1986794774 @default.
• W2154936148 cites W2035704169 @default.
• W2154936148 cites W2045783213 @default.
• W2154936148 cites W2060985892 @default.
• W2154936148 cites W2093760924 @default.
• W2154936148 cites W2097906894 @default.
• W2154936148 cites W2105024669 @default.
• W2154936148 cites W2105969273 @default.
• W2154936148 cites W2106787323 @default.
• W2154936148 cites W2110469369 @default.
• W2154936148 cites W2110590052 @default.
• W2154936148 cites W2129793485 @default.
• W2154936148 cites W2136240226 @default.
• W2154936148 cites W2139248078 @default.
• W2154936148 cites W2140469315 @default.
• W2154936148 cites W2152939220 @default.
• W2154936148 cites W2158234609 @default.
• W2154936148 cites W2166822008 @default.
• W2154936148 cites W2407483938 @default.
• W2154936148 cites W2597872842 @default.
• W2154936148 doi "https://doi.org/10.12659/msm.892730" @default.
• W2154936148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4356262" @default.
• W2154936148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25731741" @default.
• W2154936148 hasPublicationYear "2015" @default.
• W2154936148 type Work @default.
• W2154936148 sameAs 2154936148 @default.
• W2154936148 citedByCount "8" @default.
• W2154936148 countsByYear W21549361482015 @default.
• W2154936148 countsByYear W21549361482016 @default.
• W2154936148 countsByYear W21549361482017 @default.
• W2154936148 countsByYear W21549361482022 @default.
• W2154936148 countsByYear W21549361482023 @default.
• W2154936148 crossrefType "journal-article" @default.
• W2154936148 hasAuthorship W2154936148A5030366726 @default.
• W2154936148 hasBestOaLocation W21549361482 @default.
• W2154936148 hasConcept C126322002 @default.
• W2154936148 hasConcept C143998085 @default.
• W2154936148 hasConcept C146357865 @default.
• W2154936148 hasConcept C151730666 @default.
• W2154936148 hasConcept C2776256026 @default.
• W2154936148 hasConcept C2776694085 @default.
• W2154936148 hasConcept C2776907518 @default.
• W2154936148 hasConcept C2778239845 @default.
• W2154936148 hasConcept C2778424827 @default.
• W2154936148 hasConcept C2780350996 @default.
• W2154936148 hasConcept C509974204 @default.
• W2154936148 hasConcept C71924100 @default.
• W2154936148 hasConcept C86803240 @default.
• W2154936148 hasConceptScore W2154936148C126322002 @default.
• W2154936148 hasConceptScore W2154936148C143998085 @default.
• W2154936148 hasConceptScore W2154936148C146357865 @default.
• W2154936148 hasConceptScore W2154936148C151730666 @default.
• W2154936148 hasConceptScore W2154936148C2776256026 @default.
• W2154936148 hasConceptScore W2154936148C2776694085 @default.
• W2154936148 hasConceptScore W2154936148C2776907518 @default.
• W2154936148 hasConceptScore W2154936148C2778239845 @default.
• W2154936148 hasConceptScore W2154936148C2778424827 @default.
• W2154936148 hasConceptScore W2154936148C2780350996 @default.
• W2154936148 hasConceptScore W2154936148C509974204 @default.
• W2154936148 hasConceptScore W2154936148C71924100 @default.
• W2154936148 hasConceptScore W2154936148C86803240 @default.
• W2154936148 hasLocation W21549361481 @default.
• W2154936148 hasLocation W21549361482 @default.
• W2154936148 hasLocation W21549361483 @default.
• W2154936148 hasLocation W21549361484 @default.
• W2154936148 hasOpenAccess W2154936148 @default.
• W2154936148 hasPrimaryLocation W21549361481 @default.
• W2154936148 hasRelatedWork W2027766979 @default.
• W2154936148 hasRelatedWork W2046463790 @default.
• W2154936148 hasRelatedWork W2056002207 @default.
• W2154936148 hasRelatedWork W2062076456 @default.
• W2154936148 hasRelatedWork W2097791366 @default.
• W2154936148 hasRelatedWork W2098897002 @default.
• W2154936148 hasRelatedWork W2357026567 @default.
• W2154936148 hasRelatedWork W2373876840 @default.
• W2154936148 hasRelatedWork W2404042595 @default.
• W2154936148 hasRelatedWork W2414950399 @default.
• W2154936148 hasVolume "21" @default.
• W2154936148 isParatext "false" @default.
• W2154936148 isRetracted "false" @default.
• W2154936148 magId "2154936148" @default.
• W2154936148 workType "article" @default.